Clearmind Medicine starts Phase IIa CMND-100 trial in alcohol use disorder patients

• Clearmind Medicine launched a Phase IIa stage in its Phase I/IIa trial of CMND-100 for alcohol use disorder.
• Results have not been presented; the update covers trial initiation and early enrollment rather than clinical outcomes.
• Six patients have enrolled so far, starting the first multiple-dose treatment phase in participants with moderate-to-severe alcohol use disorder.
• Study aims to assess safety, tolerability, and early signs of benefit, supporting a potential scalable, non-hallucinogenic psychedelic-derived treatment approach.
• A prior independent safety review supported progression from the initial healthy-volunteer safety phase into later dosing stages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010737PRIMZONEFULLFEED9819348) on September 01, 2026, and is solely responsible for the information contained therein.